Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434496 | 0.87 | IDO1 (0.50) | PTPRCMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL11578615 | 0.81 | HIF1A (0.48) | PTPRCMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL13840595 | 0.80 | ALDH1A1 (0.42) | PTPRCMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL14806830 | 0.80 | DAO (0.39) | PTPRCMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL14179209 | 0.76 | CA1 (0.35) | PTPRCMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL8600436 | 0.75 | PTPRC (0.49) | PTPRCMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL5886422 | 0.75 | PTPRC (0.49) | PTPRCMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL30496126 | 0.75 | MAPT (0.53) | PTPRCMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL5886509 | 0.75 | PTPRC (0.49) | PTPRCMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL13445016 | 0.75 | PTPRC (0.49) | PTPRCMAPTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0876368-A1 | USE OF MONO- OR DIKETONE TETRACYCLIC DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF | LABORATOIRE INNOTHERA Société Anonyme (FR) | 1998-11-11 | — | — | EP | claimed |
| WO-1997021709-A1 | USE OF MONO- OR DIKETONE TETRACYCLIC DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF | LABORATOIRE INNOTHERA (FR) | 1997-06-19 | — | — | WO | claimed |
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143383-A1 | Pharmaceutical compounds | CHRNA10, OPRM1, SCN10A | PTPRC 3881/4885MAPT 3990/4885MEN1 2842/4885 |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | TOP1, TOP2A, TOP2B | PTPRC 2451/4885MAPT 4710/4885MEN1 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.